ATE283926T1 - Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor - Google Patents

Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor

Info

Publication number
ATE283926T1
ATE283926T1 AT96930357T AT96930357T ATE283926T1 AT E283926 T1 ATE283926 T1 AT E283926T1 AT 96930357 T AT96930357 T AT 96930357T AT 96930357 T AT96930357 T AT 96930357T AT E283926 T1 ATE283926 T1 AT E283926T1
Authority
AT
Austria
Prior art keywords
antibodies
alpha chain
receptor
human interleukin
antibodies against
Prior art date
Application number
AT96930357T
Other languages
English (en)
Inventor
Masamichi Koike
Akiko Furuya
Kazuyasu Nakamura
Akihiro Iida
Hideharu Anazawa
Nobuo Hanai
Kiyoshi Takatsu
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE283926T1 publication Critical patent/ATE283926T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96930357T 1995-09-11 1996-09-11 Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor ATE283926T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23238495 1995-09-11
PCT/JP1996/002588 WO1997010354A1 (fr) 1995-09-11 1996-09-11 Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine

Publications (1)

Publication Number Publication Date
ATE283926T1 true ATE283926T1 (de) 2004-12-15

Family

ID=16938396

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96930357T ATE283926T1 (de) 1995-09-11 1996-09-11 Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor

Country Status (11)

Country Link
US (5) US6018032A (de)
EP (1) EP0811691B1 (de)
JP (1) JP3946256B2 (de)
KR (1) KR100259828B1 (de)
CN (1) CN1241944C (de)
AT (1) ATE283926T1 (de)
AU (1) AU690474B2 (de)
CA (1) CA2205007C (de)
DE (1) DE69633973T2 (de)
ES (1) ES2233974T3 (de)
WO (1) WO1997010354A1 (de)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (es) * 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
AU767731B2 (en) * 1998-05-20 2003-11-20 Kyowa Hakko Kirin Co., Ltd. Gene recombinant antibodies
JP3679406B2 (ja) * 1998-05-20 2005-08-03 協和醗酵工業株式会社 遺伝子組換え抗体
FR2783326B1 (fr) 1998-09-10 2000-12-01 Immunotech Sa Procede de detection ou de quantification des basophiles et des eosinophiles
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) * 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
DE60038252T2 (de) * 1999-09-30 2009-03-19 Kyowa Hakko Kogyo Co., Ltd. Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3
EP1229125A4 (de) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk Verfahren zur herstellung eines polypeptids
US7404953B2 (en) * 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
CA2402417A1 (en) * 2000-03-02 2001-09-07 Kyowa Hakko Kogyo Co., Ltd. Method of separating and purifying protein
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
ATE402192T1 (de) 2000-03-03 2008-08-15 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2412494C (en) * 2000-06-22 2012-10-23 Genentech, Inc. Agonist anti-trk-c monoclonal antibodies
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
CA2424977C (en) * 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
RS51829B (sr) * 2001-08-23 2012-02-29 Genmab A/S. Ljudska antitela specifična za interleukin 15 (il-15)
CA2458627C (en) 2001-08-31 2013-09-10 Kyowa Kirin Co., Ltd. Human cdr-grafted antibody and antibody fragment thereof
EP1500400A4 (de) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk Arzneimittel mit antikörper-zusammensetzung
JP2003310275A (ja) * 2002-04-30 2003-11-05 Kyowa Hakko Kogyo Co Ltd ヒトインスリン様成長因子に対する遺伝子組換え抗体
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
EP1388544A1 (de) * 2002-07-31 2004-02-11 D. Collen Research Foundation vzw Anti-Idiotypische Antikörper gegen Factor VIII-Inhibitor und Verwendungen davon
WO2004058178A2 (en) 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
ATE492562T1 (de) 2003-09-24 2011-01-15 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin- like growth factor
WO2005035583A1 (ja) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Ｉｌ－５受容体に特異的に結合する抗体組成物
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
US7326567B2 (en) * 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
ATE557042T1 (de) * 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper
JP4954709B2 (ja) * 2004-10-28 2012-06-20 協和発酵キリン株式会社 子宮内膜症治療剤
AU2006232287B2 (en) * 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
CA2611726C (en) 2005-06-10 2017-07-11 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
WO2007066698A1 (ja) 2005-12-06 2007-06-14 Kyowa Hakko Kogyo Co., Ltd. 抗ｐｅｒｐ遺伝子組換え抗体
EP2009101B1 (de) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
WO2007142277A1 (ja) 2006-06-06 2007-12-13 Kyowa Hakko Kirin Co., Ltd. ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体
ES2429407T3 (es) * 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
AU2008208288B2 (en) 2007-01-24 2014-04-03 Kyowa Kirin Co., Ltd. Genetically recombinant antibody composition having enhanced effector activity
US20110236374A1 (en) 2007-01-24 2011-09-29 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
KR100855299B1 (ko) 2007-02-16 2008-08-29 건국대학교 산학협력단 인간 ｉｌ-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 ｉｌ-32측정법
JPWO2008114733A1 (ja) 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Ｃｌａｕｄｉｎ−４抗体
MX376656B (es) * 2007-05-14 2025-03-07 Kyowa Kirin Co Ltd Metodos para reducir niveles de basófilos.
ES2595638T3 (es) * 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
CA2708065C (en) * 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
JP5532401B2 (ja) 2007-12-05 2014-06-25 協和発酵キリン株式会社 ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体
EP2238170B1 (de) 2008-01-31 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antikörper gegen humanes cd39 und ihre verwendung zur hemmung der regulatorischen t-zell-aktivität
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
CA2729567C (en) 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
US8268592B2 (en) 2008-07-17 2012-09-18 Kyowa Hakko Kirin Co., Ltd Anti-system ASC amino acid transporter 2 (ASCT2) antibody
EP2311864A4 (de) 2008-08-13 2013-07-31 Kyowa Hakko Kirin Co Ltd Rekombinante protein-s-zusammensetzung
WO2010040766A1 (en) 2008-10-07 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
JP5139517B2 (ja) * 2008-12-05 2013-02-06 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
PT2374883T (pt) 2008-12-26 2016-10-20 Kyowa Hakko Kirin Co Ltd Anticorpo anti-cd4
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP3002296B1 (de) 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla-antikörper und ihre verwendung
EP2826789A1 (de) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten Region eines Antikörpers
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
ES2829423T3 (es) 2009-04-20 2021-05-31 Kyowa Kirin Co Ltd Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo
EP2463369A4 (de) 2009-08-07 2013-09-18 Kyowa Hakko Kirin Co Ltd Humanisierter antikörper gegen amyloid-b-oligomere
SG177679A1 (en) 2009-08-07 2012-02-28 Kyowa Hakko Kirin Co Ltd Humanized anti-amyloid-b oligomer antibody
CA2773579C (en) 2009-09-10 2019-01-15 Kyowa Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
ES2602971T3 (es) 2010-03-02 2017-02-23 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo modificado
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
WO2011118739A1 (ja) 2010-03-26 2011-09-29 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
US9040671B2 (en) 2010-07-23 2015-05-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for cancer management targeting Co-029
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
EP2647706B1 (de) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
EP2654789B1 (de) 2010-12-22 2018-05-30 Orega Biotech Antikörper gegen humanes cd39 und ihre verwendung
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
BR112013022052A2 (pt) 2011-03-01 2016-11-22 Novo Nordisk As ligantes antagonísticos de dr3
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
EP3147297B1 (de) 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Gegen icos gerichtete antikörper und verwendungen davon
CA2835603A1 (en) 2011-05-09 2012-11-15 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
JP2014516960A (ja) 2011-05-19 2014-07-17 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ヒトｈｅｒ３抗体及びその使用
JPWO2012176779A1 (ja) 2011-06-20 2015-02-23 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
CA2839508A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
EP2543678A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543679A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543677A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
CN109134658B (zh) 2011-10-31 2022-10-14 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
US20140328839A1 (en) * 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
WO2014001368A1 (en) 2012-06-25 2014-01-03 Orega Biotech Il-17 antagonist antibodies
CN104411720B (zh) 2012-07-02 2018-05-11 协和发酵麒麟株式会社 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
CA2893794C (en) 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
EP2733153A1 (de) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur Herstellung von Immunkonjugaten und Verwendungen davon
DK3199552T3 (da) 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
US9207238B2 (en) 2012-12-07 2015-12-08 Kyowa Hakko Kirin Co., Ltd. Anti-FOLR1 antibody
HK1210713A1 (en) 2012-12-27 2016-05-06 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
AU2014306956B2 (en) 2013-08-12 2019-11-21 Astrazeneca Ab Methods for reducing exacerbation rates of asthma using benralizumab
SMT202100152T1 (it) 2013-08-12 2021-05-07 Astrazeneca Ab Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab
RU2728578C2 (ru) 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
WO2015034052A1 (ja) 2013-09-05 2015-03-12 国立大学法人 宮崎大学 ヒトインテグリンａ６ｂ４と特異的に反応する抗体
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
WO2015057668A1 (en) 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
CA2926089C (en) * 2013-10-24 2022-08-30 Medimmune, Llc Stable, aqueous antibody formulations
CN105849125B (zh) 2013-11-07 2020-05-15 国家医疗保健研究所 神经调节蛋白变构抗her3抗体
US10544231B2 (en) 2014-04-16 2020-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
US20170226209A1 (en) 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
DK3271729T3 (da) 2015-03-18 2020-12-14 Janssen Vaccines & Prevention Bv Analyser til rekombinante ekspressionssystemer
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US20180071413A1 (en) 2015-04-07 2018-03-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Non-invasive imaging of tumor pd-l1 expression
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
AU2016272399B2 (en) * 2015-06-01 2021-09-09 Kyowa Kirin Co., Ltd. Therapeutic agent and therapeutic method for pulmonary hypertension
JP2018525029A (ja) 2015-07-07 2018-09-06 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） ミオシン１８ａに対する特異性を有する抗体およびその使用
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
EP3371225A2 (de) 2015-11-04 2018-09-12 AstraZeneca AB Dipeptidylpeptidase-4 und periostin als prädiktoren einer klinischen reaktion auf eosinophilgerichtete therapeutische wirkstoffe bei eosinophilen erkrankungen
AU2016361462B2 (en) 2015-11-27 2023-09-21 Csl Limited CD131 binding proteins and uses thereof
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
MX2018010295A (es) 2016-02-26 2019-06-06 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
CA3027452A1 (en) * 2016-06-14 2017-12-21 Advanced Biodesign Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
ES3041722T3 (en) 2016-07-29 2025-11-14 Inst Nat Sante Rech Med Antibodies targeting tumor associated macrophages and uses thereof
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
ES3052981T3 (en) 2017-01-24 2026-01-16 Kyowa Kirin Co Ltd Therapeutic or prophylactic agent for treating radiation damage
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
CN110914430B (zh) 2017-07-13 2023-11-21 协和麒麟株式会社 抗bril抗体以及使用了该抗体的bril融合蛋白质的稳定化方法
US11912775B2 (en) 2017-07-18 2024-02-27 Kyowa Kirin Co., Ltd. Anti-human CCR1 monoclonal antibody
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
KR102764182B1 (ko) 2017-09-21 2025-02-07 임체크 테라퓨틱스 Ｂｔｎ２에 대해 특이성을 갖는 항체 및 이의 용도
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
CA3081854A1 (en) 2017-11-08 2019-05-16 Kyowa Kirin Co., Ltd. Bispecific antibody which binds to cd40 and epcam
WO2019117208A1 (ja) 2017-12-12 2019-06-20 協和発酵キリン株式会社 抗ｂｍｐ１０抗体及び該抗体を有効成分とする、高血圧および高血圧性疾患に対する治療剤
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
DK3807316T3 (da) 2018-06-18 2024-07-29 Innate Pharma Sammensætninger og fremgangsmåder til behandling af cancer
TWI857959B (zh) 2018-06-26 2024-10-11 日商協和麒麟股份有限公司 與細胞黏著分子3 結合之抗體
JP7397444B2 (ja) 2018-06-26 2023-12-13 協和キリン株式会社 コンドロイチン硫酸プロテオグリカン－５に結合する抗体
US20210380684A1 (en) 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Antibody composition
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
WO2020094609A1 (en) 2018-11-06 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
WO2020105621A1 (ja) 2018-11-20 2020-05-28 株式会社ペルセウスプロテオミクス 細胞内への鉄の取り込み阻害剤
EP3894543A1 (de) 2018-12-14 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolierte humane mhc-abgeleitete peptide und verwendungen davon zur stimulierung und aktivierung der suppressiven funktion von cd8cd45rc + cd45rc low tregs
WO2020138487A1 (ja) 2018-12-28 2020-07-02 協和キリン株式会社 ＴｆＲに結合するバイスペシフィック抗体
CN111100210B (zh) * 2019-01-30 2022-04-19 武汉九州钰民医药科技有限公司 一种Fc融合蛋白及其应用
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
JP7652705B2 (ja) 2019-03-20 2025-03-27 イムチェック セラピューティクス エスエーエス Ｂｔｎ２に対する特異性を有する抗体及びその使用
JP2022526334A (ja) 2019-03-25 2022-05-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新たなタウ種を標的化することによるタウオパチー障害の処置の方法
WO2020230899A1 (ja) 2019-05-15 2020-11-19 協和キリン株式会社 Ｃｄ４０とｆａｐに結合するバイスペシフィック抗体
WO2020230901A1 (ja) 2019-05-15 2020-11-19 協和キリン株式会社 Ｃｄ４０とｇｐｃ３に結合するバイスペシフィック抗体
TW202110479A (zh) 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
US12011459B2 (en) 2019-06-06 2024-06-18 Immatics US, Inc. Methods for manufacturing T cells by direct sorting and compositions thereof
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
WO2021023624A1 (en) 2019-08-02 2021-02-11 Orega Biotech Novel il-17b antibodies
EP4026560A4 (de) 2019-09-04 2023-10-25 Perseus Proteomics Inc. Therapeutisches mittel für polyzythämie
CN121930331A (zh) 2019-09-13 2026-04-28 协和麒麟株式会社 DcR3变体
TW202126688A (zh) 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
EP4034560A1 (de) 2019-09-27 2022-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müller-hemmungssubstanz-antikörper und verwendungen davon
WO2021066167A1 (ja) 2019-10-02 2021-04-08 国立大学法人九州大学 ヘパリン様物質の製造方法、組換え細胞及びその製造方法
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
WO2021099600A1 (en) 2019-11-22 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
US20230250180A1 (en) 2019-11-27 2023-08-10 Perseus Proteomics Inc. Therapeutic drug for carcinomatous peritonitis
EP4072682A1 (de) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper mit spezifität gegen her4 und verwendungen davon
EP4090365A1 (de) 2020-01-15 2022-11-23 Immatics Biotechnologies GmbH Antigenbindende proteine, die spezifisch prame binden
TWI888487B (zh) 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與ｃｄ３結合之雙特異性抗體
AU2021249888A1 (en) 2020-04-01 2022-10-27 Kyowa Kirin Co., Ltd. Antibody composition
CA3180683A1 (en) 2020-05-12 2021-11-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
TW202214692A (zh) 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
CN111825763B (zh) * 2020-07-15 2022-04-19 扬州大学 流感病毒ha蛋白茎部特异性单克隆抗体及其制备方法和应用
CN117903303A (zh) * 2020-08-20 2024-04-19 南京融捷康生物科技有限公司 Il-5的结合分子及其应用
AU2021335257A1 (en) 2020-09-04 2023-03-09 Merck Patent Gmbh Anti-CEACAM5 antibodies and conjugates and uses thereof
KR102697769B1 (ko) 2020-09-14 2024-08-23 아주대학교산학협력단 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도
KR102697770B1 (ko) * 2020-09-14 2024-08-23 아주대학교산학협력단 인간 IL-5Rα에 결합하는 항체 및 이의 용도
US20240288453A1 (en) 2020-10-08 2024-08-29 National University Corporation Tokai National Higher Education And Research System Method for determining medicinal effect or sensitivity of anti-transferrin receptor antibody
AU2021379882A1 (en) 2020-11-10 2023-06-29 Sanofi Ceacam5 antibody-drug conjugate formulation
US20220193238A1 (en) 2020-12-17 2022-06-23 Astrazeneca Ab Anti-il5r antibody formulations
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
PE20240779A1 (es) 2021-07-27 2024-04-17 Immatics Biotechnologies Gmbh Proteinas de union a antigenos que se unen especificamente a ct45
WO2023006919A1 (en) 2021-07-29 2023-02-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) HUMANIZED ANTI-HUMAN βIG-H3 PROTEIN AND USES THEREOF
CA3229748A1 (en) 2021-08-26 2023-03-02 Akifumi Kato Bispecific antibody that binds to cd116 and cd131
JPWO2023027164A1 (de) 2021-08-26 2023-03-02
US20250382371A1 (en) 2022-02-09 2025-12-18 National Institutes Of Biomedical Innovation, Health And Nutrition Antibody or fragment thereof that binds to fcrl1
US20250179210A1 (en) 2022-03-09 2025-06-05 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
CN114478757B (zh) * 2022-03-31 2022-07-05 深圳市人民医院 靶向新冠病毒的纳米抗体及其制备方法和应用
US20250263497A1 (en) 2022-04-19 2025-08-21 Tokai University Educational System Therapeutic agent for nk-cell tumor
KR20250049545A (ko) 2022-08-10 2025-04-11 쿄와 기린 가부시키가이샤 항fgf23 항체 또는 해당 항체 단편
EP4587473A1 (de) 2022-09-12 2025-07-23 Institut National de la Santé et de la Recherche Médicale Neue anti-itgb8-antikörper und ihre verwendungen
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
CN121358777A (zh) 2023-07-27 2026-01-16 伊玛提克斯生物技术有限公司 抗mageb2的抗原结合蛋白
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
CN121889429A (zh) 2023-09-21 2026-04-17 阿斯利康(瑞典)有限公司 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025242845A1 (en) 2024-05-22 2025-11-27 Merck Patent Gmbh Colorectal cancer treatment
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026053166A1 (en) 2024-09-06 2026-03-12 Medimmune Limited Anti-il5r-alpha treatment for acute exacerbations of asthma and copd

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02257891A (ja) * 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JP2900039B2 (ja) 1989-09-22 1999-06-02 聖志 高津 マウスインターロイキン５レセプターに対する抗体
US5453491A (en) * 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
TW280833B (de) * 1990-12-27 1996-07-11 Hoffmann La Roche
HUT67943A (en) 1992-02-06 1995-05-29 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
JP3108497B2 (ja) 1992-02-13 2000-11-13 株式会社巴技研 重錘式引張試験機の油圧装置
ES2233974T3 (es) * 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6639385B2 (en) * 2001-08-07 2003-10-28 General Motors Corporation State of charge method and apparatus

Also Published As

Publication number Publication date
CA2205007C (en) 2010-12-14
CN1189190A (zh) 1998-07-29
DE69633973T2 (de) 2005-12-22
WO1997010354A1 (fr) 1997-03-20
CN1241944C (zh) 2006-02-15
ES2233974T3 (es) 2005-06-16
AU690474B2 (en) 1998-04-23
US7238354B2 (en) 2007-07-03
KR970707160A (ko) 1997-12-01
AU6943896A (en) 1997-04-01
KR100259828B1 (ko) 2000-06-15
US6018032A (en) 2000-01-25
EP0811691B1 (de) 2004-12-01
US20050272918A1 (en) 2005-12-08
DE69633973D1 (de) 2005-01-05
JP3946256B2 (ja) 2007-07-18
US20030096977A1 (en) 2003-05-22
EP0811691A4 (de) 2000-01-05
EP0811691A1 (de) 1997-12-10
HK1005096A1 (en) 1998-12-24
US20070048304A1 (en) 2007-03-01
US6538111B1 (en) 2003-03-25
CA2205007A1 (en) 1997-03-20
US7179464B2 (en) 2007-02-20

Similar Documents

Publication Publication Date Title
ATE283926T1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
DE69636748D1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
KR950700414A (ko) 사람 인터루킨-4에 대한 사람화 모노클로날 항체의 클로닝 및 발현(Cloning and expression of humanized monoclonal antibodies against human interleukin-4)
EP1069185A4 (de) Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DE68927459D1 (de) Nachweis einer neurologischen Krankheit oder einer Funktionsstörung
WO1990010709A3 (en) Monoclonal antibodies for metallic cations on small molecules
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
PT712863E (pt) Anticorpos monoclonais humanizados e quimericos que reconhecem o receptor do factor de crescimento epidermico (egf-r); utilizacao diagnostica e terapetica
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
EP0413763A4 (en) Method for the production of monoclonal antibodies utilizing a germfree animal
DE60034564D1 (de) Menschlicher cytokinrezeptor
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
GR3025630T3 (en) Monoclonal antibody against human IgE
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
IT1264083B1 (it) Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
MY104917A (en) Monoclonal antibodies and methods for diagnosis of phytophora infection
DE69124317D1 (de) Monoklonale Antikörper gegen Leptosphaeria
EP0332421A3 (en) Monoclonal antibodies recognizing human psti, hybridomas producing the same, and their preparation and use
DK0574461T3 (da) Humaniserede, monoklonale højaffinitetsantistoffer
ITTO911003A0 (it) Metodo rapido per l'identificazione dello s.aureus, kit diagnostico per l'esecuzione di tale metodo, anticorpi monoclonali contro la glucosaminidasi dello s. aureus e ibridoma per la produzione di tali anticorpi.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties